Under a settlement agreement, the former CEO of Vyera
A joint petition outlining the settlement has been filed in federal court in Manhattan, where James and the US Federal Trade Commission filed a lawsuit in January 2020. They alleged that the company and former executives violated antitrust law by increasing the price of a crucial drug. through
“Vyera and Mulleady, as well as Martin Shkreli, have shamelessly engaged in illegal conduct that has allowed them to maintain their exorbitant and monopolistic price of a life-saving drug – leaving the pharmaceutical brothers to get rich, while d ‘others were paying the price,’ said James.
The trial in the New York and FTC case against Shkreli is scheduled to begin on December 14. He is already serving a seven-year sentence for securities fraud committed while running two hedge funds.
Mulleady’s attorney, Kenneth David of Kasowitz Benson Torres LLP, declined to comment.
The allegations in the civil case are separate from what landed Shkreli behind bars, although the drug at the center of the case – Daraprim – is the same. Shkreli started
The FTC and New York say the company then increased the price and used a complex web of contractual restrictions to block generic versions.
(Updates with details on the lawsuit against Shkreli.)
To contact the reporter on this story:
To contact the editors responsible for this story:
Tina Davis, Steve Stroth
© 2021 Bloomberg LP All rights reserved. Used with permission.